SCHEMBL1097404

SCHEMBL1097404

CCS(=O)(=O)N(Cc1ccc(F)c(OC)c1)c1sc2ccccc2c1C(C)(C)O

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.42
TAS2R14 Q9NYV8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098624 0.89 TRPM8 (0.45) TRPM8SMN1; SMN2MAPT
SCHEMBL1099780 0.86 TRPM8 (0.56) TRPM8
SCHEMBL1099472 0.84 TRPM8 (0.42) TRPM8TAS2R14
SCHEMBL1099436 0.83 TRPM8 (0.40) TRPM8TAS2R14SMN1; SMN2POLBMAPT
SCHEMBL1097439 0.82 MAPT (0.33) TRPM8MAPT
SCHEMBL1099717 0.81 TRPM8 (0.38) TRPM8
SCHEMBL1099082 0.81 TRPM8 (0.33) TRPM8
SCHEMBL1099038 0.75 TAS2R14 (0.38) TAS2R14SMN1; SMN2
SCHEMBL1098370 0.75 TRPM8 (0.69) TRPM8
SCHEMBL1099986 0.74 TRPM8 (0.55) TRPM8MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 CN disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885TAS2R14 182/4885SMN1; SMN2 643/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885TAS2R14 182/4885SMN1; SMN2 643/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885TAS2R14 182/4885SMN1; SMN2 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.